As illustrated in Figure 1, since the introduction of JQ1 by Mitsubishi in 2010 as the first efficient BRD4 inhibitor, both academic and industrial sectors have dedicated significant efforts to develop an array of BRD4 inhibitors for breast cancer treatment, with a particular focus on triple-negative breast cancer (TNBC) (Gajjela and Zhou, 2023). Here, BRD4 is linked to breast carcinoma.